IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis

Implications for therapy

Chen Yen Yang, Xiong Ma, Koichi Tsuneyama, Shanshan Huang, Toru Takahashi, Naga P. Chalasani, Christopher Bowlus, Guo Xiang Yang, Patrick S Leung, Aftab A. Ansari, Linda Wu, Ross L. Coppel, M. Eric Gershwin

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The interleukin (IL)-12/IL-23-mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC). To address the cytokine microenvironment specifically in the liver, we examined the localized expression of cytokine subunits and their corresponding receptors using previously optimized immunohistochemistry with an extensive panel of antibodies directed at IL-12p70, IL-12p35, interferon-gamma (IFN-γ), IL-12RB2, IL-23p40, IL-23p19, IL-17, and IL-23R using liver from PBC (n=51) and non-PBC (n=80) control liver disease patients. Multiple portal tracts in each patient were blindly evaluated and individually scored. We report herein that although IL-12/Th1 and IL-23/Th17 staining was detected in all of the liver sections, they were primarily localized around the damaged interlobular bile ducts in PBC. Most important, Th17 skewing was prominent in advanced PBC patients with intensive secretion of IL-23p19 by inflamed hepatocytes around IL-23R, IL-12RB2, and IFN-γ expressing degenerated cholangiocytes. Our novel finding on the direct association of Th17 skewing and disease severity illustrates the significance of the IL-23/Th17 pathway in the perpetuation of IL-12/Th1-mediated immunopathology in PBC. Furthermore, localized IL-23p19 production by hepatocytes may enhance profibrotic Th17 signaling and proinflammatory IFN-γ production that contribute to PBC pathology. Conclusion: Our data emphasize the pathogenic relevance of IL-12/Th1 and IL-23/Th17 in the evolution of PBC. Of significance, however, the shift from a Th1 to a Th17 imbalance at advanced stages of the disease suggests the necessity to consider modulation of the IL-23/Th17 pathway as a potential target for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)1944-1953
Number of pages10
JournalHepatology
Volume59
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Interleukin-23
Biliary Liver Cirrhosis
Interleukins
Interleukin-12
Interferon-gamma
Therapeutics
Hepatocytes
Liver
Cytokines
Interleukin-17
Bile Ducts
Liver Diseases
Immunohistochemistry
Pathology
Staining and Labeling

ASJC Scopus subject areas

  • Hepatology

Cite this

IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis : Implications for therapy. / Yang, Chen Yen; Ma, Xiong; Tsuneyama, Koichi; Huang, Shanshan; Takahashi, Toru; Chalasani, Naga P.; Bowlus, Christopher; Yang, Guo Xiang; Leung, Patrick S; Ansari, Aftab A.; Wu, Linda; Coppel, Ross L.; Gershwin, M. Eric.

In: Hepatology, Vol. 59, No. 5, 2014, p. 1944-1953.

Research output: Contribution to journalArticle

Yang, CY, Ma, X, Tsuneyama, K, Huang, S, Takahashi, T, Chalasani, NP, Bowlus, C, Yang, GX, Leung, PS, Ansari, AA, Wu, L, Coppel, RL & Gershwin, ME 2014, 'IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy', Hepatology, vol. 59, no. 5, pp. 1944-1953. https://doi.org/10.1002/hep.26979
Yang, Chen Yen ; Ma, Xiong ; Tsuneyama, Koichi ; Huang, Shanshan ; Takahashi, Toru ; Chalasani, Naga P. ; Bowlus, Christopher ; Yang, Guo Xiang ; Leung, Patrick S ; Ansari, Aftab A. ; Wu, Linda ; Coppel, Ross L. ; Gershwin, M. Eric. / IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis : Implications for therapy. In: Hepatology. 2014 ; Vol. 59, No. 5. pp. 1944-1953.
@article{bf08538cfe014e789288b11f3cd93642,
title = "IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy",
abstract = "The interleukin (IL)-12/IL-23-mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC). To address the cytokine microenvironment specifically in the liver, we examined the localized expression of cytokine subunits and their corresponding receptors using previously optimized immunohistochemistry with an extensive panel of antibodies directed at IL-12p70, IL-12p35, interferon-gamma (IFN-γ), IL-12RB2, IL-23p40, IL-23p19, IL-17, and IL-23R using liver from PBC (n=51) and non-PBC (n=80) control liver disease patients. Multiple portal tracts in each patient were blindly evaluated and individually scored. We report herein that although IL-12/Th1 and IL-23/Th17 staining was detected in all of the liver sections, they were primarily localized around the damaged interlobular bile ducts in PBC. Most important, Th17 skewing was prominent in advanced PBC patients with intensive secretion of IL-23p19 by inflamed hepatocytes around IL-23R, IL-12RB2, and IFN-γ expressing degenerated cholangiocytes. Our novel finding on the direct association of Th17 skewing and disease severity illustrates the significance of the IL-23/Th17 pathway in the perpetuation of IL-12/Th1-mediated immunopathology in PBC. Furthermore, localized IL-23p19 production by hepatocytes may enhance profibrotic Th17 signaling and proinflammatory IFN-γ production that contribute to PBC pathology. Conclusion: Our data emphasize the pathogenic relevance of IL-12/Th1 and IL-23/Th17 in the evolution of PBC. Of significance, however, the shift from a Th1 to a Th17 imbalance at advanced stages of the disease suggests the necessity to consider modulation of the IL-23/Th17 pathway as a potential target for therapeutic intervention.",
author = "Yang, {Chen Yen} and Xiong Ma and Koichi Tsuneyama and Shanshan Huang and Toru Takahashi and Chalasani, {Naga P.} and Christopher Bowlus and Yang, {Guo Xiang} and Leung, {Patrick S} and Ansari, {Aftab A.} and Linda Wu and Coppel, {Ross L.} and Gershwin, {M. Eric}",
year = "2014",
doi = "10.1002/hep.26979",
language = "English (US)",
volume = "59",
pages = "1944--1953",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis

T2 - Implications for therapy

AU - Yang, Chen Yen

AU - Ma, Xiong

AU - Tsuneyama, Koichi

AU - Huang, Shanshan

AU - Takahashi, Toru

AU - Chalasani, Naga P.

AU - Bowlus, Christopher

AU - Yang, Guo Xiang

AU - Leung, Patrick S

AU - Ansari, Aftab A.

AU - Wu, Linda

AU - Coppel, Ross L.

AU - Gershwin, M. Eric

PY - 2014

Y1 - 2014

N2 - The interleukin (IL)-12/IL-23-mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC). To address the cytokine microenvironment specifically in the liver, we examined the localized expression of cytokine subunits and their corresponding receptors using previously optimized immunohistochemistry with an extensive panel of antibodies directed at IL-12p70, IL-12p35, interferon-gamma (IFN-γ), IL-12RB2, IL-23p40, IL-23p19, IL-17, and IL-23R using liver from PBC (n=51) and non-PBC (n=80) control liver disease patients. Multiple portal tracts in each patient were blindly evaluated and individually scored. We report herein that although IL-12/Th1 and IL-23/Th17 staining was detected in all of the liver sections, they were primarily localized around the damaged interlobular bile ducts in PBC. Most important, Th17 skewing was prominent in advanced PBC patients with intensive secretion of IL-23p19 by inflamed hepatocytes around IL-23R, IL-12RB2, and IFN-γ expressing degenerated cholangiocytes. Our novel finding on the direct association of Th17 skewing and disease severity illustrates the significance of the IL-23/Th17 pathway in the perpetuation of IL-12/Th1-mediated immunopathology in PBC. Furthermore, localized IL-23p19 production by hepatocytes may enhance profibrotic Th17 signaling and proinflammatory IFN-γ production that contribute to PBC pathology. Conclusion: Our data emphasize the pathogenic relevance of IL-12/Th1 and IL-23/Th17 in the evolution of PBC. Of significance, however, the shift from a Th1 to a Th17 imbalance at advanced stages of the disease suggests the necessity to consider modulation of the IL-23/Th17 pathway as a potential target for therapeutic intervention.

AB - The interleukin (IL)-12/IL-23-mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC). To address the cytokine microenvironment specifically in the liver, we examined the localized expression of cytokine subunits and their corresponding receptors using previously optimized immunohistochemistry with an extensive panel of antibodies directed at IL-12p70, IL-12p35, interferon-gamma (IFN-γ), IL-12RB2, IL-23p40, IL-23p19, IL-17, and IL-23R using liver from PBC (n=51) and non-PBC (n=80) control liver disease patients. Multiple portal tracts in each patient were blindly evaluated and individually scored. We report herein that although IL-12/Th1 and IL-23/Th17 staining was detected in all of the liver sections, they were primarily localized around the damaged interlobular bile ducts in PBC. Most important, Th17 skewing was prominent in advanced PBC patients with intensive secretion of IL-23p19 by inflamed hepatocytes around IL-23R, IL-12RB2, and IFN-γ expressing degenerated cholangiocytes. Our novel finding on the direct association of Th17 skewing and disease severity illustrates the significance of the IL-23/Th17 pathway in the perpetuation of IL-12/Th1-mediated immunopathology in PBC. Furthermore, localized IL-23p19 production by hepatocytes may enhance profibrotic Th17 signaling and proinflammatory IFN-γ production that contribute to PBC pathology. Conclusion: Our data emphasize the pathogenic relevance of IL-12/Th1 and IL-23/Th17 in the evolution of PBC. Of significance, however, the shift from a Th1 to a Th17 imbalance at advanced stages of the disease suggests the necessity to consider modulation of the IL-23/Th17 pathway as a potential target for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=84899480316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899480316&partnerID=8YFLogxK

U2 - 10.1002/hep.26979

DO - 10.1002/hep.26979

M3 - Article

VL - 59

SP - 1944

EP - 1953

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -